Protecting Our Pharmaceutical Supply Chain from China Act of 2020
USA116th CongressHR-6482| House
| Updated: 7/13/2020
Mike Gallagher
Republican Representative
Wisconsin
Cosponsors (11)
Committees (6)
• Ways and Means Committee• Oversight and Investigations Subcommittee• Health Subcommittee• Veterans' Affairs Committee• Armed Services Committee• Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Protecting Our Pharmaceutical Supply Chain from China Act of 2020 This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing Chinese ingredients, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Armed Services, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Oversight and Investigations.
Health
AsiaBusiness expensesChinaDrug safety, medical device, and laboratory regulationGovernment information and archivesHealth care costs and insuranceHealth programs administration and fundingHealth technology, devices, suppliesIncome tax deductionsManufacturingMilitary medicineMilitary procurement, research, weapons developmentPrescription drugsPublic contracts and procurementTrade restrictionsVeterans' medical care
Protecting Our Pharmaceutical Supply Chain from China Act of 2020
USA116th CongressHR-6482| House
| Updated: 7/13/2020
Protecting Our Pharmaceutical Supply Chain from China Act of 2020 This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing Chinese ingredients, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Armed Services, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Oversight and Investigations.
Mike Gallagher
Republican Representative
Wisconsin
Cosponsors (11)
Committees (6)
• Ways and Means Committee• Oversight and Investigations Subcommittee• Health Subcommittee• Veterans' Affairs Committee• Armed Services Committee• Energy and Commerce Committee
Health
Related Bills
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
AsiaBusiness expensesChinaDrug safety, medical device, and laboratory regulationGovernment information and archivesHealth care costs and insuranceHealth programs administration and fundingHealth technology, devices, suppliesIncome tax deductionsManufacturingMilitary medicineMilitary procurement, research, weapons developmentPrescription drugsPublic contracts and procurementTrade restrictionsVeterans' medical care